Moderna, Inc. (MRNA)
S&P 500 Gains and Losses Today: Moderna Plunges After Big Cut to Sales Forecast
Major U.S. equities indexes were mixed to start a new trading week ahead of inflation data that could provide some clarity on the interest-rate outlook for 2025. Earnings reports from the largest U.S. banks are also set for release this week.
Moderna slashes 2025 sales forecast, shares sink
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plunged almost 20% after the drugmaker pre-announced fiscal 2024 sales below expectations. The company expects sales of $3 billion to $3.1 billion, below the Street consensus of $3.3 billion.
Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%
Shares of pharmaceutical giant Moderna (MRNA) plunged Monday after the company cut its 2025 revenue forecast by $1 billion.
Why Moderna Stock Just Crashed 21%
Moderna's (MRNA -21.95%) sales are slowing down, and Moderna stock is going down -- a lot.
Moderna Stock Heads for Worst Day Ever on Forecast Cut
Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates.
Moderna Stock Heads for Worst-Ever Day After Reducing Revenue Forecast
Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates.
Cramer's Stop Trading: Moderna
CNBC's Jim Cramer explains why he is keeping an eye on shares of Moderna.
Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance
Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting initiative. The post Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance appeared first on Investor's Business Daily.
Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives
Moderna Inc. MRNA stock plunged on Monday after the company announced business updates and progress across its pipeline. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses.
Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion
Moderna lowered its 2025 sales guidance by roughly $1 billion, as it continues to cut costs. The biotech company now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.
Moderna's stock tumbles to post-COVID lows after revenue outlook disappoints
Moderna's stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.
Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast.
The company said Monday that it expects 2025 revenue of between $1.5 billion and $2.5 billion.
